Selected research
Industry Research
Lacosamide Industry Research Report 2026
Market perspective
The global Lacosamide market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Lacosamide market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Lacosamide market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Lacosamide market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Lacosamide include UCB, Teva, Sun Pharma, Mylan, MSN Laboratories, Glenmark, Aurobindo Pharma, Apotex and Amneal Pharmaceuticals, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Lacosamide market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Lacosamide.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Lacosamide Market by Company
UCB
Teva
Sun Pharma
Mylan
MSN Laboratories
Glenmark
Aurobindo Pharma
Apotex
Amneal Pharmaceuticals
Alembic Pharma
Accord Healthcare
Lacosamide Segment by Type
Intravenous
Oral tablets
Oral solution
Lacosamide Segment by Application
Adults
Pediatric patients
Lacosamide Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Lacosamide market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Lacosamide and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Lacosamide.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Lacosamide companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Intravenous
- Oral tablets
- Oral solution
Applications
- Adults
- Pediatric patients
Companies covered
- UCB
- Teva
- Sun Pharma
- Mylan
- MSN Laboratories
- Glenmark
- Aurobindo Pharma
- Apotex
- Amneal Pharmaceuticals
- Alembic Pharma
- Accord Healthcare
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Lacosamide by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Intravenous
- 2.2.3 Oral tablets
- 2.2.4 Oral solution
- 2.3 Lacosamide by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Adults
- 2.3.3 Pediatric patients
- 2.4 Assumptions and Limitations
3 Lacosamide Breakdown Data by Type
- 3.1 Global Lacosamide Historic Market Size by Type (2021-2026)
- 3.2 Global Lacosamide Forecasted Market Size by Type (2027-2032)
4 Lacosamide Breakdown Data by Application
- 4.1 Global Lacosamide Historic Market Size by Application (2021-2026)
- 4.2 Global Lacosamide Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Lacosamide Market Perspective (2021-2032)
- 5.2 Global Lacosamide Growth Trends by Region
- 5.2.1 Global Lacosamide Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Lacosamide Historic Market Size by Region (2021-2026)
- 5.2.3 Lacosamide Forecasted Market Size by Region (2027-2032)
- 5.3 Lacosamide Market Dynamics
- 5.3.1 Lacosamide Industry Trends
- 5.3.2 Lacosamide Market Drivers
- 5.3.3 Lacosamide Market Challenges
- 5.3.4 Lacosamide Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Lacosamide Players by Revenue
- 6.1.1 Global Top Lacosamide Players by Revenue (2021-2026)
- 6.1.2 Global Lacosamide Revenue Market Share by Players (2021-2026)
- 6.2 Global Lacosamide Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Lacosamide Head Office and Area Served
- 6.4 Global Lacosamide Players, Product Type & Application
- 6.5 Global Lacosamide Manufacturers Established Date
- 6.6 Global Lacosamide Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Lacosamide Market Size (2021-2032)
- 7.2 North America Lacosamide Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Lacosamide Market Size by Country (2021-2026)
- 7.4 North America Lacosamide Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Lacosamide Market Size (2021-2032)
- 8.2 Europe Lacosamide Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Lacosamide Market Size by Country (2021-2026)
- 8.4 Europe Lacosamide Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Lacosamide Market Size (2021-2032)
- 9.2 Asia-Pacific Lacosamide Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Lacosamide Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Lacosamide Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Lacosamide Market Size (2021-2032)
- 10.2 South America Lacosamide Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Lacosamide Market Size by Country (2021-2026)
- 10.4 South America Lacosamide Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Lacosamide Market Size (2021-2032)
- 11.2 Middle East & Africa Lacosamide Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Lacosamide Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Lacosamide Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 UCB
- 12.1.1 UCB Company Information
- 12.1.2 UCB Business Overview
- 12.1.3 UCB Revenue in Lacosamide Business (2021-2026)
- 12.1.4 UCB Lacosamide Product Portfolio
- 12.1.5 UCB Recent Developments
- 12.2 Teva
- 12.2.1 Teva Company Information
- 12.2.2 Teva Business Overview
- 12.2.3 Teva Revenue in Lacosamide Business (2021-2026)
- 12.2.4 Teva Lacosamide Product Portfolio
- 12.2.5 Teva Recent Developments
- 12.3 Sun Pharma
- 12.3.1 Sun Pharma Company Information
- 12.3.2 Sun Pharma Business Overview
- 12.3.3 Sun Pharma Revenue in Lacosamide Business (2021-2026)
- 12.3.4 Sun Pharma Lacosamide Product Portfolio
- 12.3.5 Sun Pharma Recent Developments
- 12.4 Mylan
- 12.4.1 Mylan Company Information
- 12.4.2 Mylan Business Overview
- 12.4.3 Mylan Revenue in Lacosamide Business (2021-2026)
- 12.4.4 Mylan Lacosamide Product Portfolio
- 12.4.5 Mylan Recent Developments
- 12.5 MSN Laboratories
- 12.5.1 MSN Laboratories Company Information
- 12.5.2 MSN Laboratories Business Overview
- 12.5.3 MSN Laboratories Revenue in Lacosamide Business (2021-2026)
- 12.5.4 MSN Laboratories Lacosamide Product Portfolio
- 12.5.5 MSN Laboratories Recent Developments
- 12.6 Glenmark
- 12.6.1 Glenmark Company Information
- 12.6.2 Glenmark Business Overview
- 12.6.3 Glenmark Revenue in Lacosamide Business (2021-2026)
- 12.6.4 Glenmark Lacosamide Product Portfolio
- 12.6.5 Glenmark Recent Developments
- 12.7 Aurobindo Pharma
- 12.7.1 Aurobindo Pharma Company Information
- 12.7.2 Aurobindo Pharma Business Overview
- 12.7.3 Aurobindo Pharma Revenue in Lacosamide Business (2021-2026)
- 12.7.4 Aurobindo Pharma Lacosamide Product Portfolio
- 12.7.5 Aurobindo Pharma Recent Developments
- 12.8 Apotex
- 12.8.1 Apotex Company Information
- 12.8.2 Apotex Business Overview
- 12.8.3 Apotex Revenue in Lacosamide Business (2021-2026)
- 12.8.4 Apotex Lacosamide Product Portfolio
- 12.8.5 Apotex Recent Developments
- 12.9 Amneal Pharmaceuticals
- 12.9.1 Amneal Pharmaceuticals Company Information
- 12.9.2 Amneal Pharmaceuticals Business Overview
- 12.9.3 Amneal Pharmaceuticals Revenue in Lacosamide Business (2021-2026)
- 12.9.4 Amneal Pharmaceuticals Lacosamide Product Portfolio
- 12.9.5 Amneal Pharmaceuticals Recent Developments
- 12.10 Alembic Pharma
- 12.10.1 Alembic Pharma Company Information
- 12.10.2 Alembic Pharma Business Overview
- 12.10.3 Alembic Pharma Revenue in Lacosamide Business (2021-2026)
- 12.10.4 Alembic Pharma Lacosamide Product Portfolio
- 12.10.5 Alembic Pharma Recent Developments
- 12.11 Accord Healthcare
- 12.11.1 Accord Healthcare Company Information
- 12.11.2 Accord Healthcare Business Overview
- 12.11.3 Accord Healthcare Revenue in Lacosamide Business (2021-2026)
- 12.11.4 Accord Healthcare Lacosamide Product Portfolio
- 12.11.5 Accord Healthcare Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst